title: Evaluation of a mass measles vaccination campaign among school children aged 7-14 years old in Denizli, Turkey.
abstract: OBJECTIVE
  To determine the pre-campaign level of measles seropositivity and to evaluate the effect of a mass measles vaccination campaign on measles seroposivity among primary school children in Denizli, Turkey.
  
  
  METHODS
  The study was completed in two socioeconomically different areas of Denizli, Turkey, with a sample size of 520 students. One primary school from each area and one classroom from each grade were randomly included in the sample. Before and 2-months after the measles mass vaccinations, blood samples were collected from the students and measles specific IgGs were studied.
  
  
  RESULTS
  The pre-campaign overall seropositivity was 74.7%. Post-campaign overall seropositivity increased to 96.5%. Pre-campaign seropositivity among 8-graders was significantly lower than that in other grades (57.5%, p<0.001) and the difference was explained by the number of vaccinations 8-graders received. Except for the number of vaccination doses, other factors did not have any effect on seropositivity.
  
  
  CONCLUSIONS
  The mass measles vaccination programs have a potential to control measles for developing countries. In addition, more than one dose of measles vaccination is required for developing countries.
authors.affiliation: Department of Public Health, Pamukkale University, Denizli, Turkey.
authors.forename: A I
authors.initials: AI
authors.lastname: Bozkurt
authors.forename: M
authors.initials: M
authors.lastname: Bostanci
authors.forename: N
authors.initials: N
authors.lastname: Cevahir
authors.forename: Ahmet
authors.initials: A
authors.lastname: Ergin
authors.forename: I
authors.initials: I
authors.lastname: Sancak
authors.forename: B
authors.initials: B
authors.lastname: Yilmaz
authors.forename: B
authors.initials: B
authors.lastname: Çatak
mesh_terms: D000293:Adolescent; D002648:Child; D003906:Developing Countries; D005260:Female; D006293:Health Promotion; D006801:Humans; D008297:Male; D032541:Mass Vaccination; D008457:Measles / Q000453:epidemiology / Q000517:prevention & control*; D008458:Measles Vaccine / Q000008:administration & dosage; D017063:Outcome Assessment, Health Care; D012574:Schools; D016036:Seroepidemiologic Studies; D014421:Turkey / Q000453:epidemiology
chemical_list: D008458:Measles Vaccine
references.citation: Int J Infect Dis. 2002 Mar;6(1):42-7
references.pmid: 12044301
references.citation: Pediatr Int. 2001 Aug;43(4):379-84
references.pmid: 11472583
references.citation: J Infect Dis. 2003 May 15;187 Suppl 1:S177-85
references.pmid: 12721911
references.citation: J Infect Dis. 2003 May 15;187 Suppl 1:S217-22
references.pmid: 12721916
references.citation: Vaccine. 2003 Jan 17;21(5-6):479-84
references.pmid: 12531647
references.citation: Vaccine. 2001 Sep 14;19(32):4644-51
references.pmid: 11535312
references.citation: J Infect Dis. 2003 May 15;187 Suppl 1:S63-8
references.pmid: 12721893
references.citation: J Infect Dis. 2003 May 15;187 Suppl 1:S69-73
references.pmid: 12721894